Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) are effective for non-small cell lung cancers (NSCLC) with EGFR-activating mutations. However, most responders develop resistance. Efatutazone, a novel peroxisome proliferator-activated receptor gamma (PPARγ) agonist, is currentl...

Descripción completa

Detalles Bibliográficos
Autores principales: Serizawa, Masakuni, Murakami, Haruyasu, Watanabe, Masaru, Takahashi, Toshiaki, Yamamoto, Nobuyuki, Koh, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317891/
https://www.ncbi.nlm.nih.gov/pubmed/24698130
http://dx.doi.org/10.1111/cas.12411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317891/
https://www.ncbi.nlm.nih.gov/pubmed/24698130
http://dx.doi.org/10.1111/cas.12411

Ejemplares similares